Merck and Co Inc (MRK) - News Archive

Underperformance and Inventory Challenges: Analyzing Merck & Co Inc s Stock and Inventory Turnover RatioMerck & Co Inc (NYSE: MRK) has been struggling to keep up with the overall market performance in recent weeks. Not...

RAHWAY, N.J. - Merck, a leading global pharmaceutical company, and Orion Corporation, a Finnish pharmaceutical company, have announced the mutual exercise of an option to convert their ongoing co-development and co-comm...

In a significant regulatory development, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of patritumab deruxtecan (HER3-DXd), co-develo...

In a significant development for animal healthcare, Merck Animal Health has obtained approval from the U.S. Department of Agriculture (USDA) for NOBIVAC NXT Canine Flu H3N2, a highly anticipated RNA-particle technology...

Rahway, N.J. - In a landmark development, Merck Animal Health, operating as MSD Animal Health outside the U.S. and Canada, a division of Merck & Co., Inc. (NYSE: MRK), proudly announces the U.S. Department of Agricultur...

Breaking New Ground: Merck s Pioneering Efforts with KEYTRUDA and Financial Triumphs Highlighted Merck Takes a Leap with FDA s Priority Review for KEYTRUDA Plus Chemotherapy for Malignant Pleural Mesothelioma Merck & Co...

Boosting its cancer-fighting arsenal, pharmaceutical powerhouse Merck & Co., also known internationally as MSD, secured the European Commission s approval for KEYTRUDA (pembrolizumab) plus platinum-containing chemothera...

Merck, a leading pharmaceutical company, announced disappointing results from the Phase 3 KEYLYNK-006 trial which assessed the efficacy of combining anti-PD-1 therapy KEYTRUDA with maintenance PARP inhibitor LYNPARZA in...

In recent news, pharmaceutical giant Merck has completed the acquisition of Harpoon Therapeutics, enhancing its oncology pipeline and solidifying its position as a leading innovator in cancer treatments. Additionally, M...

Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, have recently revealed compelling phase 2 data from a clinical trial involving their investigational combination therapy. The study eva...

Merck, a leading pharmaceutical company, has received a positive opinion from the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) for its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in...

Merck Animal Health to Acquire Elanco s Aqua Business for $1.3 BillionMerck Animal Health, the division of Merck & Co., Inc., has recently made a significant move in the industry by acquiring the aqua business of Elanco...

IntroductionPharmaceutical giant Merck (NYSE: MRK) has announced its plans to acquire Harpoon Therapeutics, Inc. (Nasdaq: HARP) for $680 million, aiming to further diversify and strengthen its oncology pipeline. This st...

Merck Animal Health, the United States and Canada’s branch of the renowned Merck & Co., Inc. (NYSE:MRK), today announced a significant development in their line of animal care products. Their innovative BRAVECTO (flural...

Merck Ends KEYLYNK-008 Trial for Metastatic Lung Cancer Treatment Amidst Revenue Growth in Q3 2023Merck, known as MSD outside of the United States and Canada, has made the decision to halt the Phase 3 KEYLYNK-008 trial...